Potential deleterious effects of PD-1-targeted therapy on NAFLD progression could also affect immunotherapy-treated patients with extrahepatic cancer types who suffer from concomitant NAFLD. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatotic liver disease.